Table 1 Patient and treatment baseline characteristics.

Country GNI per capita (1000$)

27.1 ± 13.6

24.0 ± 13.2

27.0 ± 13.4

28.6 ± 14.5

0.03

Age (yrs)

8.5 ± 5.8

7.7 ± 5.9

8.7 ± 5.8

8.1 ± 5.8

0.18

Male gender

550 (55%)

50 (56.2%)

388 (54.3%)

112 (56.9%)

0.79

Renal diagnosis

0.24

   CAKUT

424 (42.4%)

44 (49.4%)

291 (40.7%)

89 (45.2%)

   Glomerulopathy

388 (38.8%)

30 (33.7%)

292 (40.8%)

66 (33.5%)

   Other

189 (18.9%)

15 (16.9%)

132 (18.5%)

42 (21.3%)

Comorbidities

355 (35.5%)

38 (42.7%)

250 (35.0%)

67 (34.0%)

0.32

eGFR at PD start (ml/min/1.73 m²)

8.0 (5.3)

7.3 (5.1)

7.9 (5.2)

8.8 (5.6)

0.01

Urine output (L/m²/d)

0.61 (0.94)

0.53 (0.85)

0.63 (0.93)

0.56 (1.05)

0.80

PD modality

0.51

   CAPD

222 (22.6%)

23 (25.8%)

156 (21.8%)

43 (21.8%)

   APD

759 (77.4%)

60 (67.4%)

547 (76.5%)

152 (77.2%)

   Other

13 (1.3%)

6 (6.7%)

6 (0.8%)

1 (0.5%)

Biocompatible PD fluid use

428 (42.8%)

33 (37%)

316 (44.2%)

79 (40.1%)

0.31

Height SDS

−1.9 ± 1.7

−1.6 ± 2.1

−1.8 ± 1.6

−2.3 ± 1.8

<0.001

None

595 (59.4%)

54 (60.7%)

428 (59.9%)

113 (57.4%)

0.01

Oral nutritional supplements

218 (21.8%)

24 (27%)

160 (22.4%)

34 (17.3%)

NG tube

92 (9.2%)

6 (6.7%)

69 (9.6%)

17 (8.6%)

Gastrostomy

96 (9.6%)

5 (5.6%)

58 (8.1%)

33 (16.7%)

Amino acid PD fluid use

12 (1.2%)

4 (4.5%)

5 (0.6%)

3 (1.5%)

0.01

Growth hormone use

64 (6.4%)

3 (3.4%)

50 (7.0%)

11 (5.6%)

0.37

Hemoglobin (g/L)

10.8 ± 1.9

11.0 ± 2.1

10.8 ± 1.9

10.8 ± 1.8

0.61

Serum albumin (g/l)

35.8 ± 6.9

36.2 ± 5.4

35.6 ± 7.2

36.2 ± 6.6

0.512

Blood urea (mg/dl)

96 (63)

93 (64)

97 (63)

93 (62)

0.52

Serum bicarbonate (mM)

23.9 ± 4.3

23.7 ± 4.1

23.9 ± 4.2

24.2 ± 4.7

0.63

Serum phosphorus (mM)

1.8 ± 0.6

1.8 ± 0.6

1.8 ± 0.6

1.7 ± 0.6

0.20